3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now

Three high-yield income names are highlighted: Realty Income (O) yields ~5.8% and reported Q3 2025 AFFO/sh of $1.08 and revenue of $1.47B (+11% YoY) with 98.7% occupancy and a 15,500+ property portfolio; Pfizer (PFE) yields ~6.8%, generated $14B free cash flow in the last 12 months and reported 2024 revenues of $63.6B (+7% operational, +12% ex-COVID) while pursuing large acquisitions (Seagen $43B, Metsera) and an oncology/obesity pipeline; Verizon (VZ) yields just under 7%, posted Q3 2025 revenue of $33.8B (+1.5% YoY), consolidated net income of $5.1B, nine‑month FCF of $15.8B, and is executing a cost-cutting/turnaround including ~13,000 layoffs and debt reduction. Each company’s long dividend history and current yields are framed as attractive for long-term income investors, though risks include patent cliffs (Pfizer), business restructuring and subscriber pressures (Verizon), and sector-specific risks for real estate (Realty Income).

Analysis

Market structure: Net-lease REITs (O) and grocery/convenience-anchored landlords are the immediate winners — high occupancy (98.7%) and predictable NNN rent recapture (103.5%) preserve AFFO and make O less rate-sensitive than mall landlords. Large-cap pharma (PFE) with $14B FCF and the Seagen/Metsera assets benefit from scale and diversified revenue as COVID sales fade; telcos (VZ) face pricing pressure but generate strong FCF to fund dividends while executing a multi-quarter turnaround. Cross-asset: higher equity yields compress relative to core IG bonds (watch 10y moves ±50bp); REIT and telco equity vols will rise with any rate shock, lifting options premia and CDS spreads on high-debt telcos.

Risk assessment: Key tail risks — a +100bp rapid move in Treasury yields could knock REIT NAVs ~8–12% in 3–6 months and force dividend trimming if leverage re-prices; failed late-stage oncology or GLP-1 trials for Metsera could remove Pfizer upside and pressure its multiple quickly. Time buckets: immediate (days) — quarterly reports and short-term volatility; short-term (weeks–months) — FDA readouts, enrollment/earnings cadence; long-term (12–36 months) — Pfizer oncology commercialization and Verizon restructuring cadence. Hidden dependencies include tenant concentration shifts in O’s Europe exposure and Verizon’s reliance on prepaid growth to offset postpaid churn.

Key Decisions for Investors

• Establish a 2–3% tactical long position in Realty Income (O) over 2–4 weeks to average in; simultaneously sell 1–3 month covered calls 5–8% OTM to boost yield. Hard stop: liquidate if AFFO per share misses consensus by >4% or portfolio occupancy falls below 97% within two quarters.
• Allocate 1–2% to a directional Pfizer (PFE) options structure: buy 9–15 month call spread (buy 25–30% OTM, sell ~50% OTM) to capture upside from Seagen/Metsera catalysts while capping premium. Take-profit: +80% on spread; stop-loss: reduce/exit on any negative pivotal FDA decision or if trailing-12m FCF declines >20% y/y.
• Initiate a cautious 1–2% position in Verizon (VZ) only after a >3% price pullback that pushes yield above ~6.8%; hedge with 3–6 month 3–5% OTM protective puts or buy a put spread sized at 50% of the equity position. Exit/trim if postpaid phone net losses continue for two consecutive quarters or unsecured debt/EBITDA breaches 4.5x.
• Short-duration tactical pair: long O (target 2%) vs. short a mall-focused REIT or REIT ETF (target 2%) for 3–9 months to exploit net-lease vs. mall divergence; unwind if 10y Treasury falls >50bp (re-rating risk) or if O’s spread to VNQ compresses <100bp.